Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab…

Background Patients with advanced urothelial carcinoma have poor overall survival after
platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or …

Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …

Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

Background The treatment of advanced renal cell carcinoma has been revolutionised by
targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials …

Background Few options exist for patients with locally advanced or metastatic urothelial
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety …

Background More than half of all patients with advanced urothelial cancer cannot receive
standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …

Background Survival outcomes are poor for patients with metastatic urothelial carcinoma
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …